ArticleCardiovascular diabetology2026

Cardiovascular outcomes of empagliflozin-GLP-1RA combination therapy in type 2 diabetes: EMPRISE study.

Phyo T Htoo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.